Company intelligence / Profile preview
Dyve Biosciences
Camarillo, California, United Statesdyvebio.com ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
Completed a successful Phase 2 study in 2022 with DYV700, which met its clinically relevant endpoint of reducing pain caused by the acidic microenvironment of acute gouty arthritis. Preclinical data for DYV800 (oncology candidate) was presented at the American Association for Cancer Research 2023 Annual Meeting.
- Therapeutic areas
- RheumatologyImmunologyDermatologyOncologyNeurology
- Modalities
- pH modulation therapies
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
H. Lee Moffitt Cancer Center & Research Institute
Beyond the preview
Go deeper on Dyve Biosciences.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Dyve Biosciences.